---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-25-000657"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:23:00.487634+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IGC Pharma Phase 2 CALMA trial shows significant agitation reduction in Alzheimer's patients

## Summary
- Phase 2 interim: CMAI total score improvement -10.46 at week 6 (p=0.042, Cohen d=0.79) vs placebo.
- Sleep disturbance improved 71% at week 2 (p=0.012) and 78% at week 6 (p=0.02) on NPI-12 sleep subdomain.
- Phase 1 (n=13): no SAEs; agitation reduced significantly across all doses (p<0.05 each) on NPI agitation domain.
- Genotype-dependent PK: intermediate CYP2C9 metabolizers had longer IGC-AD1 half-life, potential for personalized dosing.
- Phase 2 CALMA trial targeting full enrollment of 146 participants for agitation in Alzheimer's dementia.

## SEC filing metadata
- accession: 0001185185-25-000657
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518525000657/0001185185-25-000657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518525000657/igc8k061425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-25-000657
- JSON: https://secwatch.observer/filing/0001185185-25-000657.json
- Plain text: https://secwatch.observer/filing/0001185185-25-000657.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.